QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFirst Affiliated Hospital of Harbin Medical University

About this trial

The revascularization treatment of multi vessel coronary artery disease (MVD) has always been a complex and important field in the treatment of coronary heart disease. The relative benefits of PCI and CABG vascular reconstruction strategies have always been a controversial topic in the field of MVD treatment. At present, SYNTAX score is the most commonly used imaging scoring system in clinical practice for quantitatively evaluating the complexity of coronary artery MVD, preliminary selection of revascularization strategies, and risk stratification. However, the SYNTAX score is entirely based on anatomical information of the lesion, and the assessment of the degree of coronary artery ischemia caused by the lesion is not accurate enough. Relying solely on anatomical structures for scoring may overestimate the harm of non ischemic lesions. The functional SYNTAX score (FSS) combines functional assessment of coronary artery lesions with anatomical structure scoring, only including lesions with hemodynamic significance, effectively optimizing the traditional SYNTAX scoring system. Compared with traditional SYNTAX scoring, FSS can reduce the number of high-risk patients, objectively evaluate the functional significance of lesions, and guide PCI treatment, significantly improving clinical prognosis.

Quantitative flow ratio (QFR) is a novel method for evaluating the functional significance of coronary artery stenosis. However, it is currently unclear whether FSS based on QFR can achieve objective and accurate risk stratification, guide the selection of revascularization strategies, and improve the long-term prognosis of patients with coronary artery MVD. Higher quality prospective clinical trials need to be designed for verification.

Therefore, this study will use a functional SYNTAX scoring system based on QFR (QFR-FSS) to conduct a prospective, multicenter, randomized controlled clinical trial to evaluate the guiding value of QFR-FSS in selecting revascularization strategies for patients with coronary artery MVD and its impact on long-term cardiovascular prognosis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years old;

Diagnosed as MVD patient by coronary angiography (≥ 50% stenosis in ≥ 2 major vessels);

Plan to undergo PCI or CABG treatment, and ensure that the contrast images meet the imaging quality requirements for QFR analysis;

Voluntarily sign the informed consent form, be able to participate in randomization and cooperate in completing all follow-up visits.

Disqualifiers

Acute myocardial infarction requires emergency PCI;

Severe left ventricular dysfunction (LVEF<30%) or cardiogenic shock;

The quality of coronary angiography images is poor, such as vascular overlap, respiratory artifacts, projection angles less than 25 °, or frame rates less than 15 frames per second;

Failure of QFR analysis due to severe calcified lesions (determined by the central laboratory);

Trial design

Design model

Parallel

Treatments tested in this trial

  • Traditional SYNTAX scoring

    Procedure/Surgery

    Using traditional SYNTAX scoring to guide the selection of revascularization strategies

  • QFR-Based Functional SYNTAX Score System

    Procedure/Surgery

    Using QFR-Based Functional SYNTAX Score System to guide the selection of revascularization strategies

Treatment groups

1,200 Participants
are divided into 2 treatment groups
Group A: Traditional SYNTAX scoring (SS)Active comparator 1 intervention
Group B: QFR-Based Functional SYNTAX Score System (QFR-FSS)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The incidence of major adverse cardiovascular events (MACE)

The incidence of major adverse cardiovascular events (MACE) 2 years after PCI or CABG surgery, defined as the composite endpoint of all-cause mortality, myocardial infarction, and ischemia driven revascularization.

Time frame
2 years

Secondary outcomes

1

Composite endpoint of cardiogenic death and myocardial infarction

Composite endpoint of cardiogenic death and myocardial infarction

Time frame
2 years
2

Disease success rate

Disease success rate: including lesion success evaluated by contrast imaging (evaluated by the central laboratory, with a visual residual stenosis degree of less than 30% and TIMI blood flow grade 3 for lesions treated with stent implantation); The residual stenosis degree of lesions treated with balloon dilation is less than 50% visually, TIMI blood flow grade 3, and the functional evaluation of lesions is successful (evaluated by the central laboratory, QFR ≥ 0.80 immediately after surgery).

Time frame
2 years
3

Clinical success rate

Clinical success rate: On the basis of successful imaging lesions at 30 days, 1 month, 6 months, 1 year, and 2 years after surgery, the incidence of MACE within the same hospitalization period (up to 7 days).

Time frame
2 years
4

The incidence of myocardial infarction

The incidence of myocardial infarction at 30 days, 1 month, 6 months, 1 year, and 2 years after surgery, including perioperative myocardial infarction (SCAI definition) and spontaneous myocardial infarction.

Time frame
2 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: